Compare Biogen Inc (BIIB) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Peloton Interactive Inc — how do they compare? Biogen Inc trades at $207.81 (market cap $30.13B), while Peloton Interactive Inc trades at $5.42 (market cap $2.46B). The key difference: Biogen Inc is far larger — about 12.2× Peloton Interactive Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | PTON | |
|---|---|---|
Market Cap | $30.13B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $9.00 |
52-Week Low | $128.93 | $3.71 |
Enterprise Value | $37.20B | $2.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Peloton Interactive (PTON) trades at $5.45, down 1.09% on the day, reflecting ongoing investor caution despite achieving its first full-year net profit in fiscal 2026. The stock shows a bearish technical trend with key support at $5, while fundamentals highlight a challenging revenue decline to $2.4B in 2026, though net income turned positive at $63M. Analyst sentiment is mixed, with a 'Hold' consensus amid concerns over subscriber losses and a muted 2027 outlook.
The outlook remains cautious; profitability improvements and cost control offer a foundation, but persistent revenue declines and high debt levels pose significant risks. Investors should weigh the company's turnaround progress against competitive pressures and execution challenges in a saturated fitness market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
